Dr Reddy's Labs (DRREDDY)

FairStock Score: 69/100 — STEADY

Score breakdown: P/E: 2/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Strong ROCE of 22.7% showing efficient capital utilization
• Steady sales growth of 4.4% indicating operational stability
• Operates in defensive pharmaceutical sector with consistent demand

Concerns

• Significant profit decline of 14.4% affecting dividend sustainability
• Very low dividend yield of 0.6% for income investors
• Poor DhanIQ score of 3/10 indicating multiple fundamental weaknesses

AI Analysis

Dr Reddy's Labs is a Slow Grower company — a major pharmaceutical player with a market value of Rs 1.1 lakh crore, trading at Rs 1,300 per share. For income-focused investors, the company presents a mixed picture. The data indicates a dividend yield of just 0.6%, which is quite modest compared to other mature companies. However, the underlying business shows some resilience with sales growing at 4.4% annually, suggesting steady operational momentum. The concerning aspect is the profit decline of 14.4%, which directly impacts dividend sustainability. With a price-to-earnings ratio of 19.3, the stock appears reasonably valued for a pharmaceutical company. The return on capital employed stands at a healthy 22.7%, indicating efficient use of shareholder money. However, the DhanIQ score of 3 out of 10 suggests significant weaknesses that investors may consider carefully. Analysis suggests that while Dr Reddy's operates in the defensive pharmaceutical sector, the combination of declining profits and low dividend yield makes it less attractive for income-seeking investors. The company's ability to maintain and grow dividends will largely depend on reversing the current profit decline trend.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer